Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 2/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | DAO | P14920 | 1/20 | 0.43 |
| ▸ | PGR | P06401 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 4/20 | 0.41 |
| ▸ | MMP13 | P45452 | 4/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29411565 | 1.00 | ALDH1A1 (0.60) | ALDH1A1MEN1CYP3A4MAPTTSHR | |
| SCHEMBL29411387 | 0.83 | MAPT (0.67) | ALDH1A1MEN1CYP3A4MAPTTSHR | |
| SCHEMBL21045240 | 0.83 | MAPT (0.67) | ALDH1A1MEN1CYP3A4MAPTTSHR | |
| SCHEMBL21045290 | 0.80 | MEN1 (0.62) | ALDH1A1MEN1CYP3A4MAPTTSHR | |
| SCHEMBL29411536 | 0.80 | MEN1 (0.62) | ALDH1A1MEN1CYP3A4MAPTTSHR | |
| SCHEMBL21045140 | 0.78 | MAPT (0.66) | ALDH1A1MEN1CYP3A4MAPTTSHR | |
| SCHEMBL29411648 | 0.78 | MAPT (0.66) | ALDH1A1MEN1CYP3A4MAPTTSHR | |
| SCHEMBL29411432 | 0.77 | ALDH1A1 (0.70) | ALDH1A1MEN1CYP3A4MAPTTSHR | |
| SCHEMBL21045549 | 0.77 | ALDH1A1 (0.70) | ALDH1A1MEN1CYP3A4MAPTTSHR | |
| SCHEMBL21045524 | 0.77 | MEN1 (0.63) | ALDH1A1MEN1CYP3A4MAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220089539-A1 | TUBULIN INHIBITORS | LIN BIOSCIENCE INC. (TW) | 2022-03-24 | — | — | US | disclosed |
| US-20220089539-A1 | TUBULIN INHIBITORS | LIN BIOSCIENCE INC. (TW) | 2022-03-24 | — | — | US | disclosed |
| US-11040945-B2 | Tubulin inhibitors | LIN BIOSCIENCE PTY LTD. | 2021-06-22 | — | — | US | disclosed |
| US-11040945-B2 | Tubulin inhibitors | LIN BIOSCIENCE PTY LTD. | 2021-06-22 | — | — | US | disclosed |
| WO-2019113242-A1 | TUBULIN INHIBITORS | Lin BioScience, LLC (US) | 2019-06-13 | — | — | WO | disclosed |
| US-20190169127-A1 | TUBULIN INHIBITORS | LIN BIOSCIENCE INC. (TW) | 2019-06-06 | — | — | US | disclosed |
| US-20190169127-A1 | TUBULIN INHIBITORS | LIN BIOSCIENCE INC. (TW) | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089539-A1 | TUBULIN INHIBITORS | TUBB3, TUBB1, TUBB | ALDH1A1 3048/4885MEN1 955/4885CYP3A4 3925/4885 |
| US-11040945-B2 | Tubulin inhibitors | TUBB3, TUBB1, TUBB | ALDH1A1 3048/4885MEN1 955/4885CYP3A4 3925/4885 |
| US-20190169127-A1 | TUBULIN INHIBITORS | TUBB3, TUBB1, TUBB | ALDH1A1 3048/4885MEN1 955/4885CYP3A4 3925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.